Responding to citizen petitions filed by Abbvie Inc., of North Chicago, and Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., the FDA said it doesn't need to do a rulemaking to assign a therapeutic equivalency (TE) rating to testosterone drugs approved on the 505(b)(2) path.